Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Study of real world outcomes with elotuzumab-based therapies for relapsed and refractory myeloma finds median PFS for EPd was 4.8 months and for ERd was 17.28 months; median OS 2.55 and was 5.64 years, respectively.”
Title: Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
Authors: Ricardo D. Parrondo, Saurav Das, Hanna Sledge, Leif Bergsagel, Rafael Fonseca, Nelson Leung, Prashant Kapoor, Morie Gertz, Francis Buadi, Angela Dispenzieri, Jamie Elliott, Andre Fernandez, Caitlin Flott, Asher A. Chanan-Khan, Vivek Roy and Sikander Ailawadhi.
You can read the Full Article in Blood Cancer Journal.
More posts featuring Robert Orlowski.
